Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed EBIT Margin for 6 consecutive years, with 19.55% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 1675.0% year-over-year to 19.55%, compared with a TTM value of 8.53% through Dec 2025, up 2510.0%, and an annual FY2025 reading of 8.53%, up 2510.0% over the prior year.
  • EBIT Margin was 19.55% for Q4 2025 at Xeris Biopharma Holdings, up from 9.05% in the prior quarter.
  • Across five years, EBIT Margin topped out at 19.55% in Q4 2025 and bottomed at 289.55% in Q2 2021.
  • Average EBIT Margin over 5 years is 70.49%, with a median of 37.52% recorded in 2023.
  • The sharpest move saw EBIT Margin tumbled -7402bps in 2021, then soared 21480bps in 2022.
  • Year by year, EBIT Margin stood at 222.55% in 2021, then surged by 79bps to 45.77% in 2022, then surged by 52bps to 22.17% in 2023, then soared by 113bps to 2.79% in 2024, then soared by 600bps to 19.55% in 2025.
  • Business Quant data shows EBIT Margin for XERS at 19.55% in Q4 2025, 9.05% in Q3 2025, and 6.27% in Q2 2025.